Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome




Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

  • Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1
  • Median time-to-next-treatment (TTNT), the study’s primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1
  • Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1

GALASHIELS, Scotland & MARLOW, England–(BUSINESS WIRE)–Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one of the largest real-world evaluations of mogamulizumab in Germany and add to the growing body of evidence supporting its use in routine clinical practice.1-3


Conducted as a company-sponsored, multicentric, non-interventional, combined retro-prospective real-world study across 18 centres throughout Germany, MINT brought together cutaneous T‑cell lymphoma (CTCL) specialists to evaluate treatment outcomes with mogamulizumab in a real-world setting, with time-to-next-treatment (TTNT) as the study’s primary endpoint.1 The study captured a broad and heterogeneous patient population, including clinically relevant subgroups such as patients with large cell transformation (LCT) and folliculotropic mycosis fungoides (fMF), and stratified by disease stage and mogamulizumab-associated rash (MAR) status, providing insights that complement evidence generated through controlled clinical studies.1,4

MF and SS are forms of CTCL, a type of non-Hodgkin’s lymphoma that manifests on the skin,5 though the disease can also involve the blood, lymph nodes and visceral organs.6 Symptoms can include persistent, itchy and scaly rashes, changes in skin colour and patches, plaques and/or tumours.7 These visible and often difficult-to-hide symptoms can make everyday activities harder and significantly affect patients’ quality of life, including their work, relationships and social lives,8 and for some patients the disease can progress to affect long-term survival.9

“For patients living with mycosis fungoides and Sézary syndrome, understanding how treatments perform outside the controlled setting of clinical trials is critically important. The final MINT results demonstrate meaningful clinical outcomes across a broad patient population treated in routine practice and highlight the value of collaborative real-world research in helping clinicians make informed treatment decisions,” said Professor Chalid Assaf, Director of the Department of Dermatology and Venereology, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, Germany.

The final analysis included 109 patients, comprising 56 patients with MF and 53 patients with SS, with a median follow-up of 25.2 months.1 The majority of patients had advanced disease when they started treatment, with 83.5% at stage IIB or above.1 The study demonstrated durable treatment outcomes, reporting a median TTNT of 14.9 months, a best overall response rate of 62.4%, and an overall median progression-free survival of 20.2 months.1 Median overall survival was not estimable at the time of analysis due to the limited number of deaths observed, despite up to 71 months of follow-up in some cases.1

Looking more closely at treatment response in clinically relevant patient subgroups, exploratory analyses reported best overall response rates of 54.5% in patients with LCT (n=11; 95% CI: 23.4–83.3) and 50.0% in patients with fMF (n=12; 95% CI: 21.1–78.9). Additional exploratory analyses by disease stage showed best overall response rates of 50% in patients with early-stage disease (n=18; 95% CI: 26.0–74.0) and 64.8% in patients with advanced stage disease (n=91; 95% CI: 54.1–74.6).10 Disease control rate was also reported in patients with MAR (n=47), at 95.7%.4

TTNT is an important measure in real-world clinical practice as it reflects both disease control and the duration of clinical benefit before a patient requires an alternative treatment approach. The study reported a median TTNT of 12.0 months in patients with MF and 20.2 months in patients with SS.4 Patients also experienced improvements in quality of life, with median Skindex-29 scores improving by 38.5% from 49.1 at treatment initiation (n=21) to 30.2 at Month 12 (n=7).1

“MINT provides valuable real-world evidence from Germany on the use of mogamulizumab across the heterogeneous population of patients with mycosis fungoides and Sézary syndrome, including clinically relevant subgroups that are often underrepresented in clinical trials. By evaluating time-to-next-treatment as a clinically meaningful outcome, the study offers practical insights that can support CTCL specialists in making informed, individualised treatment decisions,” said Dr. Azeem Danish, Medical Affairs Director, DACH, Kyowa Kirin.

The investigators concluded that, in a real-world setting, mogamulizumab demonstrated a safety profile comparable to that observed in the pivotal Phase 3 MAVORIC study, while providing clinical benefits in treatment response and quality of life for patients with MF and SS.1,5 Grade 3 or higher treatment-related adverse events were reported in 38.5% of patients, most commonly drug eruption and lymphopenia.1 Serious treatment-related adverse events leading to discontinuation occurred in 22.0% of patients.1

Kyowa Kirin has supported the generation of real-world evidence in CTCL through collaborations with investigators and treatment centres across Europe. The MINT study contributes to a growing evidence base exploring outcomes in patients treated with mogamulizumab in routine clinical practice1-3 and reflects a shared commitment between investigators and industry to advancing understanding of rare cancers and improving care for patients living with CTCL.

About the MINT Study

MINT (Mogamulizumab In a Non-interventional study to evaluate the safety and outcome in mycosis fungoides and Sézary syndrome Treatment) is a German multicentric, non-interventional, retro-prospective real-world study evaluating the effectiveness and tolerability of mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Data were collected from patient medical records across 18 study sites in Germany. The primary endpoint was time-to-next-treatment, with secondary endpoints including response rate, progression-free survival, overall survival, quality of life and tolerability.1

About Kyowa Kirin

Kyowa Kirin aims to discover novel medicines with life-changing value. As a global specialty pharmaceutical company, we have invested in drug discovery and biotechnology innovation for more than 75 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our three regions: JAPAC, North America, and EMEA.

You can learn more about the business of Kyowa Kirin at: https://kyowakirininternational.com/.

About mycosis fungoides (MF) and Sézary Syndrome (SS)

MF and SS are two subtypes of cutaneous T‑cell lymphoma (CTCL), which is itself a rare form of non-Hodgkin’s lymphoma that presents and persists in the skin.5 CTCL is treatable, but is not generally considered to be curable, and there has been a clear unmet need for novel treatment options. As well as the obvious impact of symptoms upon patients, there can be significant erosions to quality of life for those caring for an individual living with CTCL.11

MF and SS are characterised by localisation of cancerous white blood cells called T lymphocytes (T cells), to the skin.9 These cancerous T cells consistently express a protein called CCR4, which enables them to move from the blood to the skin.12-14 When these cancerous T cells move to the skin, this results in the visible early skin symptoms of red patches or plaques which can resemble psoriasis or eczema in the early stages of the disease.7 Later, for some patients, skin involvement may evolve to include tumours or reddening of the majority of the skin’s surface (erythroderma).7

MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs15 and is typically indolent, characterised by skin symptoms including patches or plaques, skin redness and tumours. SS is much rarer, accounting for around 5% of CTCLs,6 and is more aggressive,7 with high levels of blood involvement.6 It can cause severe itching, erythroderma, intense scaling of the skin and hair loss.7 CTCL can take, on average, between 2 and 7 years for individuals to receive a confirmed diagnosis.16

About POTELIGEO® (mogamulizumab)

Mogamulizumab is a first-in-class humanised monoclonal antibody (mAb) directed against CC-chemokine receptor 4 (CCR4), a protein consistently expressed on cancerous cells seen in both mycosis fungoides and Sézary syndrome.12-14 Once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.17

About POTELIGEO® (mogamulizumab) in Plain Language

Mogamulizumab is a monoclonal antibody designed to recognise and attach to CCR4, a protein commonly found on certain cancerous cells in mycosis fungoides and Sézary syndrome. By targeting these cells, it helps the body’s immune system identify and destroy them.

REFERENCES

1 Assaf C DG, Schlaak M, Booken N, Oymanns M, Klespe K-C, et al. Final results from the German “Mogamulizumab In a Non-interventional study to evaluate the safety and outcome in mycosis fungoides and Sézary syndrome Treatment” (MINT) study [Abstract]. Presented at: European Organisation for Research and Treatment of Cancer – Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting; 2026 Oct 9–10; Berlin, Germany.

2 Broccoli A, Argnani L, Pileri A, Mazzoni C, Sordi B, Pimpinelli N, et al. Quality and duration of responses with mogamulizumab in cutaneous T-cell lymphomas: Insights into long-lasting outcomes. Br J Haematol. 2025;207(6):2578-82.

3 Bozonnat A, Beylot-Barry M, Dereure O, D’Incan M, Quereux G, Guenova E, et al. Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study. eClinicalMedicine. 2024;73(102679).

4 Assaf C DG, Schlaak M, Booken N, Oymanns M, Klespe K-C, et al. Final results from the German “Mogamulizumab In a Non-interventional study to evaluate the safety and outcome in mycosis fungoides and Sézary syndrome Treatment” (MINT) study [Oral presentation]. Presented at: European Organisation for Research and Treatment of Cancer – Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting; 2026 Oct 9–10; Berlin, Germany.

5 Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-204.

6 Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. Eur J Cancer. 2017;77:57-74.

7 Lymphoma Coalition. Cutaneous lymphoma – a patient’s guide. Available at: https://lymphomacoalition.org/wp-content/uploads/Cutaneous_lymphoma_-_patients_guide_-.pdf Last accessed: October 2026.

8 Martín-Carrasco P, Morillo-Andújar M, Sendín-Martín M, Conejo-Mir J. Quality of Life in Patients with Cutaneous T-Cell Lymphoma. Actas Dermo-Sifiliográficas. 2019;110(6):511-3.

9 Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015;33(32):3766-73.

10 Kyowa Kirin. Data on file. 2026.

11 Williams K, Gibson A, McNamara L, Jones T, Lloyd A. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL). J Med Econ. 2020;23:1142-50.

12 Ferenczi K, Fuhlbrigge RC, Pinkus JL, Pinkus GS, Kupper TS. Increased CCR4 Expression in Cutaneous T Cell Lymphoma. Journal of Investigative Dermatology. 2002;119(6):1405-10.

13 Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in Adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99:1505-11.

14 Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625-34.

15 Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-14.

16 Cutaneous Lymphoma Foundation. A patient’s guide to understanding cutaneous lymphoma [Internet]. 2nd ed. Cutaneous Lymphoma Foundation; 2018. Why it takes time to get a diagnosis; p. 21. Available from: https://flipbook.clfoundation.org/A_Patients_Guide/files/assets/basic-html/page29.html Last accessed: October 2026.

17 Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171-4.

Contacts

James Read

james.read@kyowakirin.com
+44 (0)7917 922566

Or email: comms@kyowakirin.com

EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement

EvoNext Holdings SA / Key word(s): Merger

EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement

12-Oct-2026 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require registration or any other measure and does not constitute an offer of securities for sale in any country.

PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
EvoNext Holdings SA (“EvoNext”) and Ascend Sport Technology AG (“Ascend”) sign transaction agreement – Ascend to go public on SIX Swiss Exchange and enter its next phase of development

  • EvoNext Holdings SA (SIX: EVE) and Ascend Sport Technology AG have signed a binding transaction agreement for a statutory merger; Ascend will become a publicly listed company through a merger into EvoNext with its existing listing on SIX Swiss Exchange
  • EvoNext valued at CHF 2.50 per share; Ascend equity valued at CHF 500 million
  • Ascend is a Swiss sports technology holding company, bringing together complementary businesses across the sports technology value chain and forming a leading global platform with AI-enabled monetisation capabilities. Ascend serves over 100 rightsholders and more than 500 brands and broadcasters in over 20 countries
  • Share placement will be targeting an appropriate free float, comprising predominantly secondary shares and a smaller primary issuance to support future growth initiatives
  • Transaction subject to approval by the extraordinary general meetings of both companies and is scheduled to be completed during the fourth quarter 2026.

Reinach / Lucerne, Switzerland, 12 October 2026 – EvoNext Holdings SA (“EvoNext”, SIX: EVE), a Swiss listed holding company, and Ascend Sport Technology AG (“Ascend”), a Swiss sports technology holding company, today announce the signing of a binding transaction agreement to combine the two companies by way of a statutory merger. The planned transaction will lead, subject to the approval of the companies’ general meetings, to the formation of a listed Swiss sports technology company with a global footprint and attractive growth prospects in the rapidly expanding sports media and advertising market. The combined company will operate under the name of Ascend Sport Technology AG and remain listed on the SIX Swiss Exchange.

Transaction structure and valuation

The parties have agreed on a valuation of EvoNext at CHF 2.50 per share. The transaction will be implemented as a statutory merger (merging of Ascend business against issuance of new EvoNext shares).

In conjunction with the transaction, EvoNext will conduct a share placement (the “Offering”). The Offering is expected to consist predominantly of secondary shares to create an attractive free float and establish a diversified institutional shareholder base, complemented by a primary issuance to support Ascend’s continued growth, strategic initiatives and general corporate purposes. All shares offered in the placement are expected to be offered at a price of CHF 2.50 per share, corresponding to the valuation agreed in connection with the merger. The shares will be placed in a multi-day accelerated book building process.

Members of the Board of Directors, executive management and shareholders of Ascend and certain shareholders of EvoNext are subject to lock-up periods of 12 and 24 months following completion of the Offering.

A premium platform for the global sports technology market

Ascend is a Swiss sports technology holding company, bringing together complementary businesses across the sports technology value chain and forming a leading global platform with AI-enabled monetisation capabilities. Ascend’s businesses serve over 100 rightsholders, including sports leagues, clubs and federations such as FIFA and UEFA, as well as more than 500 brands and broadcasters across over 20 countries. Through its premium infrastructure, and its AI-powered software and data solutions, Ascend enables rightsholders to monetise every live game through scalable and data-driven advertising.

Ascend combines recurring software revenues, long-term relationships with leading sports organisations, and proprietary technology assets, creating a highly scalable platform positioned to benefit from the ongoing digitisation of global sports advertising. While football represents the company’s largest market today, Ascend’s technology platform is designed to serve the broader sports ecosystem and is well positioned to support the increasing adoption of digital advertising, data analytics and AI-enabled monetisation solutions across a wide range of sports, leagues, federations and media rightsholders globally.

Ascend’s integrated one-stop-shop platform spans Digital Signage and Digital Overlay®, a proprietary sponsorship marketplace, audience intelligence and sponsorship ROI measurement, a high-end streaming and data analytics platform, as well as premium infrastructure.

A compelling combination

The merger combines Ascend’s established operating platform and growth trajectory with EvoNext’s public listing and capital markets infrastructure, creating a scalable public company positioned to capitalize on long-term structural growth in digital sports media, sponsorship and advertising technologies. The transaction is expected to enhance Ascend’s visibility, financial flexibility and access to growth capital, while remaining the founder-led company with the entrepreneurial spirit which has supported Ascend’s growth in the past.

Gianluca Ferrari, Chairman of the Board of Directors of EvoNext Holdings SA, said: “Ascend has built a differentiated and highly attractive founder-led business with a proven track record of growth, a global customer base and proprietary technology assets. The merger provides investors with the opportunity to participate in a leading global sports technology platform at the forefront of the digital transformation of sports media and advertising. We look forward to supporting the Ascend team as they execute on the company’s next phase of growth as a publicly listed business.”

Bernard de Roos, Founder and CEO of Ascend Sport Technology AG, said: “We are very excited about this opportunity to unlock the next phase of Ascend’s evolution. We have built a premium, fully integrated technology platform that has become the backbone of digital sports advertising for the world’s leading rightsholders, leagues, and broadcasters. The listing on SIX Swiss Exchange gives us the profile and the standing for this next phase and we open our business to investors, creating a unique opportunity to participate in the growing global sports market.”

Next steps and indicative timing

The transaction is subject to approval by the extraordinary general meetings of EvoNext and Ascend, as well as customary closing conditions. Documentation relating to the merger, including the merger report, shareholder information and invites to the extraordinary general meetings, will be published in accordance with applicable legal and regulatory requirements.

EvoNext intends to publish the offering documentation for the planned Offering shortly after its extraordinary general meeting [EvoNextholdings.com]. The transaction is scheduled to be completed during the fourth quarter of 2026.

The Board of Directors of EvoNext unanimously recommends that shareholders approve the transaction. EvoNext will inform shareholders and the market of all material developments in due course.

Contact for investors and media

EvoNext Holdings SA

investors@evonextholdings.com

susanne.muehlemann@lemongrass.agency / +41 79 223 70 81

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy securities of EvoNext Holdings SA and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. Any offer and listing of any securities in EvoNext Holdings SA (“Securities”) will be made solely by means of, and on the basis of, a prospectus which is to be published. An investment decision regarding any publicly offered Securities should only be made on the basis of such prospectus. The prospectus is expected to be published in the fourth quarter of 2026 and will be available free of charge from the accompanying bank.

This publication may contain specific forward-looking statements, e.g., statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of EvoNext Holdings SA or Ascend Sport Technology AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. EvoNext Holdings SA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). Any potential investment or investment activity to which this communication relates will be available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.

This communication does not constitute an “offer of securities to the public” within the meaning of Regulation 2017/1129 of the European Union (the “Prospectus Regulation”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”) or, in the United Kingdom (“UK”), the UK Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”). Any placements of any Securities to persons in the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation or the POATRs (as applicable), as implemented in member states of the EEA or the UK, from the requirement to produce a prospectus for offers of Securities.

Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of any potential placements in the United States, and does not intend to conduct a public offer of securities in the United States.

This communication is not for distribution in the United States, Canada, Australia, Japan or any other jurisdiction into which the same would be unlawful and does not constitute an offer of securities for sale in such countries. This communication does not constitute an offer to sell, or the solicitation of an offer to buy, securities in any jurisdiction in which is unlawful to do so.

Additional features:

File: 2026_10_12_EvoNext Holdings SA – Ad hoc – Transaction Agreement Ascend


End of Inside Information


Language: English
Company: EvoNext Holdings SA
Angensteinerstrasse 6
4153 Reinach
Switzerland
Phone: +41 61 485 20 00
E-mail: investors@evonextholdings.com
Internet: www.evonextholdings.com
ISIN: CH1262055788
Valor: 126205578
Listed: SIX Swiss Exchange
EQS News ID: 2413784

 
End of Announcement EQS News Service

2413784  12-Oct-2026 CET/CEST

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases




Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 EXPAND study evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia.

Conference Call Details:


US/Toll-Free: +1 833 461 5787
International: +1 585 542 9983
Access Code: 486697901

You may also access the call via webcast by visiting the Investors section of Mirum’s corporate website. The archived webcast will be available for replay.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), ATEBRIOZ™ (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), CHOLBAM® (cholic acid) for bile-acid synthesis disorders and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).

Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.

Contacts

Investor Contact:
Andrew McKibben
ir@mirumpharma.com

Media Contact:
Meredith Kiernan
media@mirumpharma.com

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026




Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular edema (DME)

Remigromig is the first biologic with a novel mechanism of action to demonstrate non-inferior visual acuity compared with anti-VEGF therapy in a pivotal DME trial

Despite available therapies, up to 40% of people with DME have persistent disease after six months, driving need for new approaches

RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New Orleans: BRUNELLO – 1-Year Pivotal Trial Results of Remigromig (MK-3000, formerly EYE103) for the Treatment of Diabetic Macular Edema; D. D’Amico.

In the BRUNELLO study, both remigromig dose arms met the primary endpoint independently, demonstrating non-inferiority in mean change from baseline in best corrected visual acuity (BCVA) at one year compared with monthly 0.5mg ranibizumab. Mean BCVA gains at Year 1 were +9.1 letters (95% CI, 8.1-10.1; p=0.0129, multiplicity-adjusted) with remigromig 0.5 mg and +8.7 letters (95% CI, 7.7-9.8; p=0.0222, multiplicity-adjusted) with remigromig 0.8 mg, compared with +11.8 letters with ranibizumab (95% CI, 10.7-12.8). Differences between treatment groups were within the prespecified non-inferiority margin and were not considered clinically meaningful. No secondary endpoints demonstrated superiority to ranibizumab.

While both doses of remigromig were generally well tolerated, adverse events related to proliferative diabetic retinopathy (PDR) occurred more frequently with remigromig than with ranibizumab (6.7% and 6.1% with remigromig 0.5 mg and 0.8 mg, respectively, versus 0.9%), inclusive of new-onset PDR.1 In addition, higher rates of treatment discontinuations due to adverse events were observed in the remigromig treatment arms compared with ranibizumab (4.9% and 4.5% with remigromig 0.5 mg and 0.8 mg, respectively, versus 0.9%). Additional analyses are underway to further characterize these findings. PDR rates may reflect natural disease progression in DME patients since remigromig focuses on repair and maintenance of the blood-retinal barrier rather than directly suppressing new vessel growth. PDR cases were generally manageable with standard-of-care treatment.

“Although anti-VEGF therapies remain the foundation of treatment for diabetic macular edema, up to two thirds of patients fail to achieve clinically meaningful vision gains after one year, underscoring the need to explore new biological pathways,” said Donald J. D’Amico, M.D., chair of Ophthalmology at Weill Cornell Medicine, Ophthalmologist-in-Chief, New York-Presbyterian Hospital and presenting author of the BRUNELLO study. “These findings ‒ which demonstrate for the first time that a biologic targeting the Wnt pathway can achieve visual acuity comparable to an established anti-VEGF therapy ‒ support continued evaluation of this novel approach as we look forward to additional Phase 3 results from the BAROLO study.”

“Despite important advances in care, up to 40% of patients with diabetic macular edema have persistent disease activity after six months of treatment, meaning that they do not respond or only partially respond to therapy, underscoring the need for new therapeutic approaches,” said Dr. David Guyer, founder, chief executive officer and president of EyeBio, a wholly owned subsidiary of Merck. “The BRUNELLO study provides important evidence that activating the Wnt pathway, which is involved in the repair and maintenance of the blood-retinal barrier, may offer a potential new way to help patients with DME and expand treatment options for retinal specialists and their patients.”

“The BRUNELLO results represent an important milestone for people living with diabetic macular edema, a leading cause of vision loss among people living with diabetes, which impacts nearly 1.6 million people in the U.S.,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “As the first new mechanism of action in more than 20 years to demonstrate non-inferior visual acuity compared with standard-of-care anti-VEGF therapy in a pivotal DME study, remigromig has the potential to expand treatment options for retinal specialists and patients. We thank the patients, caregivers and investigators whose participation made this study possible.”

The BRUNELLO trial data further strengthens Merck’s advancing ophthalmology pipeline, which is aimed at promoting retinal recovery by addressing specific retinal diseases associated with vascular leakage and neovascularization, including DME, neovascular (wet) age-related macular degeneration (NVAMD) and macular edema secondary to retinal vein occlusion (RVO).

Results from BRUNELLO will be discussed with regulatory authorities. Remigromig is also being evaluated in the ongoing pivotal Phase 2b/3 BAROLO study (NCT06957080) in patients with DME and in a Phase 2 proof-of-concept study (SUPER TUSCAN) in patients with NVAMD and RVO (NCT07205887).

The company is also developing MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecific antibody with a dual mechanism that directly activates the Tie2 pathway and inhibits VEGF with the goal of stabilizing retinal and choroidal blood vessels and reducing fluid accumulation in the macula. MK-8748 is currently being studied in two pivotal Phase 2b/3 trials for the treatment of NVAMD, TORRONTES (NCT07496567) and MALBEC (NCT07440225), and in two pivotal Phase 3 studies for the treatment of DME, SANGIOVESE (NCT07705555) and SYRAH (NCT07705607).

About the BRUNELLO trial

BRUNELLO is a randomized, double masked pivotal Phase 2b/3 trial (NCT06571045) evaluating the safety and efficacy of two dose levels (0.5 mg and 0.8 mg) of intravitreal (IVT) remigromig (MK-3000, formerly EYE103) versus active control 0.5mg ranibizumab in adults with DME. The trial enrolled 984 participants who were randomized 1:1:1 to receive low and high dose regimens of remigromig or ranibizumab every four weeks for the first year. In the second year, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. The primary endpoint is mean change in best-corrected visual acuity (BCVA) from baseline to week 52 in the study eye of the participants, using standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) vision testing. The key secondary endpoints at week 52 are mean change from baseline in BCVA (superiority of remigromig vs. ranibizumab), and mean change from baseline in Central Subfield Thickness (CST) (superiority of remigromig vs. ranibizumab).

About Remigromig

Remigromig (MK-3000, formerly EYE103) is an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, which is involved in the repair and maintenance of the blood-retinal-barrier. Remigromig is being studied in patients with certain retinal diseases including diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). Remigromig is administered by intravitreal injection.

About diabetic macular edema

Diabetic macular edema (DME) is a serious retinal condition and a leading cause of vision loss for people with diabetes. An estimated 1.6 million people are living with DME in the United States. DME occurs when damaged blood vessels leak into the retina, resulting in swelling in the macula, the central region of the retina crucial for precise vision necessary for everyday activities. The prevalence of DME is anticipated to rise with the increasing incidence of diabetes. While currently available treatments have helped to improve outcomes, a significant number of patients, up to 40%, do not respond or only partially respond to therapy, underscoring the need for new treatment approaches.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (http://www.sec.gov/).

1 PTs indicative of PDR: diabetic retinopathy (if LLT ‘proliferative diabetic retinopathy’), vitreous hemorrhage, iris neovascularization, retinal neovascularization, glaucoma (if LLT ‘neovascular glaucoma’), neovascularization

Contacts

Media Contacts:

Elizabeth Sell

elizabeth.sell@merck.com

Shannon Hatch

Shannon.hatch@merck.com

Investor Contacts:

Peter Dannenbaum

(732) 594-1579

Hayley Kasko

(732) 594-4237

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss




Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

  • In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks
  • UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated
  • The FDA has accepted Genentech’s Biologics License Application (BLA), with an approval decision expected by July 2027 


SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$RHHBY–Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swelling in the back of the eye due to retinal fluid) with vamikibart treatment. The data were presented at the American Academy of Ophthalmology 2026 Annual Meeting (AAO 2026) in New Orleans, LA.

Additionally, the U.S. Food and Drug Administration (FDA) has accepted Genentech’s Biologics License Application (BLA) for vamikibart for the treatment of UME. The filing acceptance is based on the results from the MEERKAT and SANDCAT studies. The FDA is expected to make a decision on approval by July 2027. If approved, vamikibart would be the first non-steroid targeted treatment for UME, with potential to establish a new standard of care. Regulatory submissions have also been filed and accepted in the European Union, China and Japan.

“These one-year results strengthen vamikibart’s clinical profile, confirming that initial visual and anatomical improvements are maintained over 52 weeks,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The acceptance of our application by the FDA and other regulatory bodies around the world brings us closer to offering a transformative, non-steroid therapy for people living with this sight-threatening condition.”

“Currently, UME is commonly treated with off-label therapies or ocular steroids, the latter carrying significant long-term side effects like glaucoma and cataract formation,” said Nisha Acharya, M.D., M.S., Distinguished Professor of Ophthalmology at UCSF and Director of the Uveitis and Ocular Inflammatory Disease Service. “Vamikibart is the first non-steroid targeted therapy to demonstrate meaningful and sustained visual and anatomical improvements in people with UME, offering a potential new treatment option that directly targets the inflammation driving this sight-threatening condition.”

The 16-week primary analysis results were presented at the AAO meeting in October 2025. In both MEERKAT and SANDCAT at 52 weeks, a numerically higher proportion of vamikibart-treated patients achieved vision gains compared to sham treatment on the primary endpoint. Key secondary endpoints showed this benefit was maintained, with sustained improvements in average change from baseline in best corrected visual acuity (BCVA) and average change from baseline in central subfield thickness (CST), a key measure of macular edema. Vamikibart demonstrated durable clinical benefit with a low treatment burden: approximately two-thirds of eligible patients required no retreatment after 16 weeks, while the majority of those who did required only one additional injection. Vamikibart was well tolerated, maintaining a favorable safety profile, with a low incidence of treatment-related ocular adverse events (AEs) and intraocular inflammation (IOI) events.

UME is the leading cause of moderate-to-severe vision loss in individuals with uveitis, predominantly affecting working-age adults. Approximately 20% of UME patients progress to sustained blindness within three years of diagnosis. Standard-of-care treatments, primarily high-dose or local corticosteroids, carry substantial long-term risks, including secondary cataracts and elevated intraocular pressure leading to glaucoma. As a targeted anti-IL-6 monoclonal antibody, vamikibart is being developed to address these clinical unmet needs and deliver sustained visual preservation.

About the MEERKAT and SANDCAT studies

MEERKAT (NCT05642312) and SANDCAT (NCT05642325) are identical Phase III, global, parallel, multicenter, randomized, double-masked, sham comparator-controlled, 52-week trials of intravitreal (IVT) vamikibart in uveitic macular edema (UME). In both trials, patients were randomized and received treatment every four weeks with either 0.25 mg vamikibart, 1 mg vamikibart or sham IVT injection, for up to 16 weeks, followed by PRN treatment through week 52. The primary endpoint of both Phase III trials was the proportion of participants with a 15 letter or more improvement from baseline in best corrected visual acuity (BCVA) at week 16. Key secondary endpoints included the average change from baseline in BCVA and CST at week 16. The safety of vamikibart was assessed through adverse events (AEs) such as treatment related ocular AEs, intraocular inflammation (IOI) and retinal occlusive vasculitis. The studies included participants with and without prior IVT treatment history and included patients with history of raised IOP and glaucoma.

About uveitic macular edema (UME)

UME is characterized by the buildup of fluid in the macula due to uveitis, an inflammatory eye condition. Although rare compared to other eye diseases, UME has a disproportionate impact on vision loss and blindness globally. It is the leading cause of moderate and severe vision loss in people with uveitis, and the most frequent sight-threatening complication in uveitis. Uveitis accounts for 10% to 20% of blindness in the United States and Europe, and up to 25% of blindness in the developing world. UME has a significant negative impact on people’s quality of life, including physical and mental health, social functioning, and visual function for day-to-day activities such as driving and reading. Steroids, the current standard of care for UME, are associated with significant serious side effects such as increased pressure in the eye, glaucoma and cataracts, and have recognized efficacy limitations.

About Vamikibart

Vamikibart is an investigational monoclonal antibody that has been specifically engineered for IVT administration. It targets interleukin-6 (IL-6), a key cytokine in the inflammatory pathway in UME. In the Phase I DOVETAIL study, vamikibart provided rapid vision improvements and resolution of macular edema in people with UME. Vamikibart was also well tolerated, with no treatment-related serious adverse events reported. Based on the promising Phase I DOVETAIL data, Genentech initiated the two identical Phase III vamikibart studies MEERKAT and SANDCAT. Vamikibart is being investigated in retinal diseases with recognized inflammatory pathways. Vamikibart has orphan drug designation in the United States and European Union.

About Genentech in Ophthalmology

Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases, including rare and inherited conditions.

About Genentech

Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Contacts

Media Contact:

Nicole Burkart

(650) 467-6800

Advocacy Contact:

Meg Harrison

(617) 694-7060

Investor Contacts:

Loren Kalm

(650) 225-3217

Bruno Eschli

+41 61 687 5284

AHF Debuts ‘Wellness on Wheels’ – New EV Mobile Clinic During ‘Pride on Paradise’

AHF Debuts ‘Wellness on Wheels’ – New EV Mobile Clinic During ‘Pride on Paradise’




AHF Debuts ‘Wellness on Wheels’ – New EV Mobile Clinic During ‘Pride on Paradise’

Launching during Las Vegas Pride weekend and with National HIV Testing Day, AHF’s State-of-the-art Chevy BrightDrop EV electric van mobile clinic makes HIV and STI testing more efficient and accessible

LAS VEGAS–(BUSINESS WIRE)–#AHFcares—AIDS Healthcare Foundation (AHF), the world’s largest nonprofit public health organization, is debuting a new environmentally friendly, electric mobile (EV) unit to increase access to free testing, prevention and treatment services for sexually transmitted infections (STI), including gonorrhea, chlamydia, syphilis and HIV. As the first nonprofit public health organization to launch the all-in-one, “wellness on wheels” concept, the organization will unveil its new vehicle—AHF’s first in the Western U.S. region—at the Pride on Paradise festival, in Las Vegas, Nevada on Saturday, October 10, 2026. AHF recently launched its inaugural Wellness on Wheels EV in Fort Lauderdale, Florida, on August 28th.

WHAT:

RIBBON-CUTTING: State-of-the-art, “Wellness on Wheels” mobile clinic offering free HIV & STI testing

WHEN:

Saturday, October 10th, 6:30 p.m. ceremony in conjunction with Pride on Paradise and National Coming Out Day

WHERE:

“Pride on Paradise” Festival

4605 W. Paradise Road, Las Vegas NV 89169

NOTE:

“Wellness on Wheels” van will be across from the Main Stage

WHO:

Chris Mejia, MS, MPH, Western Regional Director, AHF Public Health Division

Hon. Arron D. Ford, Attorney General, State of Nevada

Other speakers TBD

B-ROLL:

Tours of the new EV testing van and its HIV and STI testing services

AHF’s new EV mobile wellness unit will provide the community free access to testing and prevention services for sexually transmitted infections, including gonorrhea, chlamydia, syphilis and HIV, as well as same day access to PrEP services and linkage to HIV specialty care. Through an onsite consultation with a medical provider, the unit will also provide immediate linkage to HIV medical care for individuals who test positive for the disease, and same day access to PrEP (pre-exposure prophylaxis), an HIV prevention drug for those who are HIV negative.

Key Highlights of the EV Mobile Wellness Unit:

  • AHF is one of the first to adopt a fully electric platform for medical diagnostic services. Model refinement to move away from tradition model (engine + generator) to EV model (electric + solar), thus creating increased productivity, less setup time, generator dependency, power interruptions and mechanical interruptions.
  • This adoption creates savings by eliminating the need for fuel, routine maintenance for engine/generator and service-related items
  • Year to date, AHF has spent thousands in auto repairs on its traditional gas powered mobile vans across the country and looks now to reducing this, avoiding routine service for engine and generator, no catalytic converter, reduction in idle related issues, and charge through solar and outlet/EV charging
  • Lastly, this is a multifunctional vehicle with exam bed, phlebotomy, bathroom with sink and toilet, vaccination, centrifuge and processing area, fridge for storage, and insulated for clinical comfort and equipment stability
  • Will provide increased number of PrEP/STI panels

To learn more about AHF services and to schedule the new mobile wellness unit, visit FREESTDCHECK.org.

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 3.3 million individuals across 50 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center’s highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

Contacts

Sean Jones, AHF Senior Events Manager

(323) 793-9097 c sean.jones@ahf.org

Anthony DeFelice, Founder/CEO, Summer Communications

anthony@summercommunications.com

Ged Kenslea, Senior Director, AHF Communications

(323) 791-5526 c ged.kenslea@ahf.org

Bio-Gate AG reports first half results for 2026

Bio-Gate AG

/ Key word(s): Half Year Results

Bio-Gate AG reports first half results for 2026

09.10.2026 / 15:55 CET/CEST

The issuer is solely responsible for the content of this announcement.


 

PRESS RELEASE

 

Bio-Gate AG Reports First-Half Results for 2026

  • First-half revenue of 2.8 million euros, down from the previous year (3.4 million euros)
  • EBIT loss of 927 TEUR; cost-saving measures taking effect
  • Forecasts for full-year 2026 revenue and earnings adjusted
  • Revenue growth in the Veterinary and Measurement Technology; Derma-Cosmetics and Wound Care business segment with a temporary decline in revenue

 

Nuremberg/Bremen, October 9, 2026 – Bio-Gate AG (ISIN DE000BGAG981), a leading provider of proprietary antimicrobial technologies for human and veterinary medicine, generated consolidated revenue of 2.8 million euros in the first half of 2026 (as of June 30), a decline of just under 18 percent compared to the same period last year. Changes in the product portfolio and organizational restructuring—particularly in the derma-cosmetics and wound care business segments—led to significantly lower order volumes from two major customers for human and animal care products, respectively. The medical technology segment, which includes implant coatings, performed in line with expectations. However, revenue growth was weaker due to timing shifts related to specific dates in the completion of milestones. This was caused by delayed partial deliveries from a project partner. By contrast, the Veterinary and Measurement Services business segments increased their revenue contributions.

 

At the half-year mark, Bio-Gate reported a loss of 814 TEUR at the EBITDA level (previous year: -723 TEUR) and a loss of 927 TEUR at the EBIT level (previous year: -840 TEUR). As a result, the losses—relative to the decline in revenue—were significantly lower due to positive effects from cost-saving and efficiency measures already implemented.

 

The Executive Board is confident that the decline in revenue will be only a temporary phenomenon. Revenue is expected to return to 2025 levels as early as 2027. Growth momentum is expected to come, for example, from a new Bio-Gate medical device for scar treatment developed for a dermocosmetics customer. Preparations for the market launch are already underway. In addition, Bio-Gate is achieving significant cost savings through the reorganization of its corporate structures and processes along the value chain, thereby strengthening its profitability.

 

2026 Full-Year Forecast Revised

For the full year 2026, the Executive Board expects consolidated revenue to range between 6.0 and 6.9 million euros (previous forecast from May 2026: ±7% of the prior-year level, i.e., approximately 6.9 to 7.9 million euros; previous year’s consolidated revenue: 7.4 million euros). EBITDA is expected to range between -0.9 and -1.1 million euros, which—despite the lower revenue—is at or slightly below the previous year’s level (-0.9 million euros), as cost savings will offset part of the impact of the revenue decline. Management anticipates EBIT of between -1.1 and -1.5 million euros (previous year: -1.1 million euros).

 

Note

Bio-Gate AG’s consolidated semiannual report as of June 30, 2026, is available for download at https://www.bio-gate.de/unternehmen/

under Investor Relations/Financial Reports.

 

Financial Calendar 2026

November 24         Equity Forum, Frankfurt

 

 

Contacts

Bio-Gate AG

Neumeyerstr. 28-34

90411 Nuremberg

Germany

www.bio-gate.de

 

North America

Karl Richter

RFH BioTek Inc.

Tel: 416-407-6120

rfh@rfhBioTek.com

Toronto, Canada

 

Europe

Falk von Kriegsheim

rikutis consulting

fvk@rikutis.de

presse@bio-gate.de

Tel. +49 (0) 911 477523-222

Mobil +49 (0)172 9837109

 

About Bio-Gate AG

The medical technology company Bio-Gate AG develops and markets applications which use unique silver technology to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – thus providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG works in three fields to supply a variety of products that provide antimicrobial protection: material enhancement, surface coating and testing the antimicrobial or anti-adhesive properties of materials. The Nuremberg-based company offers systems that stretch across the entire value-adding chain, from development to approval to production. For more information, please visit www.bio-gate.de.

 

Disclaimer

This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold.


09.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Bio-Gate AG
Neumeyerstr. 28-34
90411 Nürnberg
Germany
Phone: +49 (0) 911 / 47 75 23 – 100
Fax: +49 (0) 911 / 47 75 23 – 101
E-mail: marc.lloret-grau@bio-gate.de
Internet: www.bio-gate.de
ISIN: DE000BGAG0J3
WKN: BGAG0J
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hanover, Munich (m:access), Stuttgart, Tradegate BSX
LEI Code: 391200G5LKTIOTZOXP90
EQS News ID: 2413462

 
End of News EQS News Service

2413462  09.10.2026 CET/CEST

Cantourage and Green Karat deepen strategic partnership following EU-GMP certification

Cantourage Group SE

/ Key word(s): Product Launch/Miscellaneous

Cantourage and Green Karat deepen strategic partnership following EU-GMP certification

09.10.2026 / 08:14 CET/CEST

The issuer is solely responsible for the content of this announcement.


  • Exclusive product access: Cantourage strengthens its premium portfolio across Europe and reinforces its role as a gateway to European markets for Canadian producers.
  • Greater supply-chain resilience: Direct imports of EU-GMP-certified finished products increase flexibility and strengthen supply-chain resilience.
  • Additional manufacturing capacity: Shifting production steps to certified cultivation partners creates additional capacity.

Cantourage Group SE (ISIN: DE000A3DSV01) is strengthening its position as a leading European platform for medical cannabis. Its long-standing Canadian partner Green Karat obtained EU-GMP certification effective 1 October 2026. Cantourage supported the certification process as sponsor and certification partner and is Green Karat’s exclusive distribution partner for products manufactured by Green Karat in the European Union and the United Kingdom.

The certification marks an important step in Cantourage’s strategy of helping leading international cannabis producers access the European market while securing attractive products and brands for its core European markets through exclusive partnerships.

The partnership between Cantourage and Green Karat is built on a long-standing relationship of trust. EU-GMP certification takes the collaboration to the next level: Cantourage will be able to import finished products manufactured by Green Karat directly from Canada in accordance with EU-GMP standards. This can help make products available to pharmacies across Europe sooner after harvest.

“Cantourage has been an important and trusted partner for us in Europe for many years. The company combines deep regulatory expertise with strong access to the European markets that matter to us and a clear understanding of high-quality cannabis products. Working with Cantourage on the EU-GMP certification process was therefore a natural next step. The certification creates the basis for bringing our products to patients in Europe more directly and quickly, and for continuing to grow our presence across Europe together,” said Jen-Frederick Nadeau, founder and CEO of Green Karat.

“Green Karat has been a trusted partner for many years, and this certification marks an important next step in our collaboration. By supporting our partners through EU-GMP certification, we are building a more flexible and resilient supply chain and strengthening access to high-quality products for patients and customers across Europe,” said Philip Schetter, CEO of Cantourage Group SE.

At the same time, the model offers Cantourage tangible strategic and operational benefits. Shifting production steps to EU-GMP-certified cultivation partners gives Cantourage greater flexibility across its value chain and opens up additional manufacturing capacity. A broader production footprint also reduces operational concentration risk and strengthens supply-chain resilience. This positions Cantourage to expand its business with premium products from international partners efficiently and at scale.

Green Karat is one example of Cantourage’s broader certification strategy. Cantourage is already working with other leading international producers on certification processes, which are expected to be completed by the end of 2026. The company is continuing to strengthen its role as a certification partner and as a gateway to the European market for Canadian and other international cannabis producers.

For Cantourage, the combination of exclusive partnerships, regulatory expertise and an international network of high-quality producers is a key pillar of its European growth strategy. The company intends to further develop its role as a link between leading international cannabis producers and European markets.

About Cantourage

Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and cannabis-based pharmaceuticals. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to access the growing European medical cannabis market faster, more easily and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In doing so, Cantourage consistently ensures compliance with the highest European pharmaceutical quality standards.

The Company offers pharmaceutical-grade products across all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 – DE000A3DSV01 (ISIN).

 

 


09.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX
LEI Code: 3912003NCTLO6YHA9V48
EQS News ID: 2413024

 
End of News EQS News Service

2413024  09.10.2026 CET/CEST

Clinical Screens in Melbourne, Data in Chicago, Foundational Models in Hangzhou: Tracing Medical AI’s Trillion-Dollar Value

EQS Newswire / 09/10/2026 / 14:11 UTC+8

Today, after a patient completes a chest CT scan, clinicians pull up the images, review prior test results and treatment histories, and interpret what the new findings signify. Tomorrow, the next wave of trillion-dollar medical AI companies will likely emerge from three pillars: clinician workflow systems used day-to-day, datasets spanning the entire patient care journey, and foundational models that continuously deliver new diagnostic capabilities.

Tracing this trajectory reveals three global hubs. Pro Medicus (ASX: PME) in Melbourne, Australia, built its business around imaging workflows; Tempus AI (NASDAQ: TEM) in Chicago, US, focuses on diagnostics and patient data; Diagens Tech (HKEX: 2526) in Hangzhou, China, innovates with medical imaging foundational models. As of 8 October 2026, their respective market capitalisations stood at approximately RMB 78 billion, RMB 84 billion, and RMB 22 billion.

Each company began with a distinct business focus: Pro Medicus primarily sells imaging software; Tempus generates most of its revenue from molecular diagnostics and data services; Diagens Tech deploys medical imaging large foundational models into hospitals and clinical practice. Together, they illuminate a critical industry question: if workflows and data already command high valuations, could models that continuously generate clinical capabilities become the third high-value asset class in medical AI?

This article argues that Diagens Tech is positioning itself to occupy exactly this niche. By expanding from one regulated use case to additional specialties and hospital sites, it empowers clinical specialists to build, deploy and operate thousands of custom models on one unified foundation. As AI infinitely amplifies specialist expertise, medical imaging foundational models evolve from standalone technology products into scalable platform assets.

 

A Paradigm Shift: Health Demands Answers, and Above All, Evidence

The arrival of large models in healthcare reshapes how people engage with health information. In 2026, OpenAI rolled out health features that connect to medical records and Apple Health with user consent, reporting that more than 300 million people submit health queries to ChatGPT each week. Health management may shift from sporadic web searches to continuous insight, reminders and follow-up queries. Even so, while large language models can interpret reports, they cannot validate tumour shrinkage or organ damage from that data alone, let alone deliver reliable forecasts of disease progression.

On another frontier, AI is transforming drug discovery. Google DeepMind’s AlphaGenome examines how genetic variants alter molecular properties; NVIDIA and Eli Lilly announced up to USD 1 billion joint investment over five years; Rentosertib, a candidate drug co-developed by Insilico Medicine, entered Phase Ⅲ trials in 2026. From molecular hypotheses to clinical trials, models now contribute to discovery and R&D decisions. Health management seeks to understand what occurs within the body, while drug development explores how treatments alter disease outcomes. Both rely on reproducible, observable clinical evidence.

As the primary source of clinical evidence, medical imaging covers roughly 14,000 indication-specific tasks across CT, MR, ultrasound, endoscopy, pathology, microscopy, dermatoscopy and fundus imaging, accounting for 80% of all global clinical data. According to the World Health Organization, over 25 billion medical imaging scans are performed worldwide each year. This massive volume makes imaging one of the richest, most reliable observation layers within healthcare systems. Medical records, comparatively, are human-language documentation of those core observations.

Model development and clinical trials are converging in medical imaging. Google’s MedGemma 1.5 delivers interpretation for 3D CT, MRI and pathology images, while Microsoft’s CARE‑X focuses on chest X-ray reading and lesion localisation. The Swedish MASAI randomised trial enrolled approximately 106,000 women. Within a defined breast screening pathway, the AI-assisted workflow achieved higher breast cancer detection sensitivity (80.5% versus 73.8%), with comparable false positive control (98.5% specificity in both arms). Advances in technical performance and clinical evidence are converging. The next question defining industry value centres on integrating these capabilities into clinicians’ daily tools and building sustainable revenue streams.

 

Pro Medicus’ Screens in Melbourne: Imaging Information Management Software — Embedded in Clinicians’ Daily Workflows

The “screens” referenced here refer to end‑to‑end workflow management software for clinicians to view, compare and analyse medical images. Pro Medicus’s Visage7 integrates image viewing, archiving and workflow management. Clinicians open, review and compare imaging data on this system every day. Going forward, once hospitals organise image reading, reporting and cross‑institutional collaboration around this platform, the software may become central to clinical operations.

This pathway has delivered tangible commercial outcomes. In fiscal2026, Pro Medicus recorded approximately AUD261.7million in revenue and AUD127.5million in operating cash inflow, with disclosed minimum contracted revenue of around AUD1.3billion over the next five years. The market assigns it a valuation well above its current‑period revenue. Long‑term contracts, workflow‑embedded products and proven cash‑generating capacity underpin this valuation.

Melbourne demonstrates the first key insight: in high-frequency, trust-reliant healthcare settings, the daily access portal used by clinicians is itself a valuable asset. Yet smooth image visualisation only addresses operational needs. To interpret what imaging findings mean for an individual patient, clinicians also require the patient’s diagnostic, examination and treatment context.

 

Tempus’ Data in Chicago: Connecting Single Tests to a Patient’s Lifelong Care Journey

Tempus offers a second benchmark. Its core revenue comes from molecular diagnostics – understanding disease via genetic and molecular information – linking test results, clinical records, data applications and pharmaceutical R&D needs. Its implications for the industry are that value can extend beyond diagnosis when textual data connects a patient’s long‑term disease trajectory, treatment decisions and real‑world outcomes.

In Q2 2026, Tempus generated USD382.5million in revenue, including USD289.3million from diagnostics and USD93.2million from data and applications. Tempus also disclosed delivery of the first version of its oncology foundational model to AstraZeneca. Tempus’s valuation reflects data generated by its diagnostic business, capabilities for deploying data to clinicians and pharmaceutical companies, and its sustained revenue growth.

 

Diagens Tech’s Foundational Model in Hangzhou: Turning Clinicians from Users into Creators

The promising future of medical AI emerges from a recent in-depth conversation between Dr. Ning Song, Founder and Chairman of the Board of Diagens Tech and Kevin Kelly, founding editor-in-chief of WIRED, the renowned global technology publication. Dr. Song drew an analogy between print shops and office productivity software. Document creation once required outsourced typesetting and printing, a slow and costly process. After document-editing tools became accessible on personal computers alongside printers, the volume of documents people could create exploded. Yet global healthcare still operates differently: vendors select disease areas, build AI tools independently and hand finished products to hospitals. Spending RMB 300 million over three years to build one disease-specific imaging AI tool remains common. Dr. Song envisioned a comparable shift: radiologists can leverage state-of-the-art imaging foundational models to train custom diagnostic AI rapidly, accurately and affordably for their own specialties. He described this future medtech ecosystem as “a flourishing bloom of custom clinical AI solutions”. While endorsing this innovative framework, Kevin Kelly noted that for a world-leading medical AI company, the journey to realise this vision forms its strongest competitive moat.

Medical imaging foundational models operate on a simple principle: learn general anatomy and lesion characteristics from vast libraries of CT, ultrasound and pathology scans, then adapt to targeted clinical assessments using specialty-specific patient cases. The shared foundation absorbs the heavy upfront investment, allowing new use cases to reuse existing capabilities. Diagens Tech discloses its iMedImage® foundational medical imaging model spans 19 imaging modalities and 26 clinical specialties. For certain low-data scenarios, a specialty model can be trained within two to three months using roughly 200 imaging samples. Its iMedMaaS® model training and deployment platform enables clinicians to run no-code training and on-premise deployment using in-hospital datasets. Hospitals thereby shift from purchasing off-the-shelf algorithms to defining clinical challenges and co-building tools.

For this production system to work, image volume is only the starting point; clinical expertise must be integrated into datasets. Diagens Tech reports that iMedImage® was trained on more than 80 million medical images. Its iMedLoop™ medical imaging AI R&D and production acceleration platform hosts 28.95 million annotated records, built with contributions from over 3,000 specialised professionals. A “record” refers to one sample entry, which may contain multiple images – much as a single CT scan generates sequential slices. Raw scans expose the model to diverse anatomical variations, while expert annotations identify lesion locations and classification rules. Annotation, quality control and evaluation transform raw image data into usable clinical knowledge for model training. Hospitals can also train models locally using their own data. As of mid-2026, Diagens Tech had partnered with 99 hospitals to deliver 158 model projects. New clinical challenges defined by hospitals, paired with annotation and evaluation frameworks co-developed by specialists, form building blocks for future applications. Notably, the number of models Diagens Tech trains within a single year exceeds the total volume of medical imaging AI models developed across China in the past decade.

Translating this production capacity into clinical adoption requires market-ready products and paying customers. AI AutoVision®, built on iMedImage®, is software designed to help clinicians analyse karyograms and detect abnormalities. It obtained Class III medical device registration from China’s NMPA in May 2026. In its clinical trial, the “clinician+AI” workflow delivered readings in an average of 11.3 minutes, compared with 34.1 minutes for conventional workflows. In the first half of that year, Diagens Tech generated RMB 94.541 million in model service revenue via model and technology licensing, cloud services and on-premise deployment, marking year-on-year growth of 101.1%. The registered product demonstrates how foundational models translate into clinical use, while model service revenue confirms customers are paying for model generation and delivery capacity. The vision of “flourishing bloom” therefore gains commercial substance: clinicians define new clinical challenges, and the platform continuously delivers specialty capabilities using a unified toolset.

 

The Trillion-Dollar Question: From an Imaging-AI Factory to Disease-Interpretation Infrastructure

What challenges does this “factory” need to tackle? Medical imaging diagnostics cover 14,000 indication-specific tasks. This count refers neither to hardware nor individual images, but to distinct examinations designed for separate clinical objectives. Even for chest CT, lung cancer screening, pulmonary embolism detection and pneumonia assessment represent separate indications, requiring different imaging protocols and clinician interpretation workflows. Each task demands specialised capabilities; medical imaging forms a vast, fragmented landscape of clinical requirements.

Scale brings its own constraint: many clinical conditions lack sufficient patient samples. A study published in Nature Communications identified 5,568 imaging-linked diseases and anomalies across more than 40,000 patient cases, many represented by fewer than 30 samples. The traditional “one model for one disease” paradigm requires fresh case collection, expert annotation, training and validation for every new task. Costs and timelines compound when addressing tens of thousands of niche use cases. Cross-task reusable foundational models embed shared imaging comprehension within a single foundation, allowing clinicians to adapt models using specialty-specific samples. This makes it feasible to cover these long-tail clinical needs at a manageable cost. The true expansion enabled by foundational models lies in the total volume of clinical capabilities that can be built.

This factory unlocks another capability: supporting researchers to frame new questions about disease progression. Imaging captures physical changes within the body. When linked to pathology, genetics, treatment records and patient outcomes, models can probe: which early markers signal recurrence? Which patients will respond best to a given therapy? This is AI for Science in medical imaging: identifying correlations from large-scale clinical observations and generating testable medical hypotheses. Research published in Nature Cancer has sought to infer tumour gene expression from pathology slides to predict therapeutic response.

Diagens Tech’s research advances along this same path. Its iMedImage® technical report reveals the team combined contrast-enhanced CT, clinical and pathological data to predict one-year post-surgical recurrence risk for pancreatic cancer, achieving an AUC of 0.78 across 89 external test samples. An AUC value closer to 1 denotes stronger ability to stratify patients by risk. A separate study combines cervical ultrasound and maternal clinical histories to forecast preterm birth risk. Model research is shifting its focus from “what can be observed today” to “how disease may evolve over time”. In September 2026, Diagens Tech established a joint laboratory with the Hong Kong Polytechnic University to investigate medical imaging analysis, healthcare foundational models and research workflow automation.

The logical thread spanning these three cities now forms a complete loop. Pro Medicus owns the daily software access portal for clinicians; Tempus integrates textual findings into AI-powered long-term patient journey databases for diagnostics and pharmaceutical R&D; Diagens Tech builds a production platform empowering clinicians worldwide to build new models. Its growth follows two clear vectors: expanding into more hospitals, and addressing numerous specialty AI diagnostic needs within each site. Shared foundational models cut development costs for new tasks. Extending beyond diagnosis into prognosis, patient stratification and treatment response research opens opportunities to serve academic institutions and life science companies. This reveals a new dawn for human health management, as the field shifts from Cure Medicine toward Care Medicine.

Amid the promising outlook for human well-being, the three cities, three pathways and three sets of valuations remain underappreciated. Diagens Tech’s growth journey represents humanity’s quest to manage health more effectively and precisely.

Melbourne shapes clinicians’ daily workflows, Chicago maps patients’ lifelong care journeys, and Hangzhou establishes a new benchmark for human health. At the frontiers of AI, we welcome a new era of human well‑being.

09/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program

Newron Pharmaceuticals S.p.A.

/ Key word(s): Study

Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program

08.10.2026 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program 

Management call today at 3.30 pm CEST

Newron received the anticipated FDA written communication on clinical hold at U.S. study centers and is reviewing feedback and preparing its response

ENIGMA-TRS 1 enrollment expected to be completed by mid-October; topline 12-week data expected in Q1 2027

ENIGMA-TRS 2 enrollment continuing outside the U.S., with additional clinical sites being added as planned

FDA clinical hold remains in place at U.S. study centers; Newron intends to respond upon thorough review and analysis of FDA feedback
 

Milan, Italy, and Morristown, NJ, USA – October 8, 2026, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that, further to its press release on September 25 2026, the Company has in the meantime received written communication from the U.S. Food and Drug Administration (FDA) regarding the clinical hold at U.S. study centers in its Phase 3 ENIGMA-TRS 2 study with evenamide.  Newron is conducting a thorough review of the FDA’s feedback and the available data and intends to submit its response upon completion.

Newron continues to advance the Phase 3 ENIGMA-TRS development program. ENIGMA-TRS 1 enrollment is expected to be completed by mid-October, with topline 12-week data expected in Q1 2027. ENIGMA-TRS 2 enrollment continues outside the U.S. Additional clinical sites are being added as planned.

FDA Clinical Hold and ENIGMA-TRS Program Update

The FDA’s concern relates to the known risk that certain members of the class of sodium channel blockers may trigger arrhythmias which in turn can lead to serious cardiovascular events or seizures. Evenamide is a glutamate modulator via its action as a selective voltage-gated sodium channel blocker.

In its written communication, the FDA notes four deaths among patients treated with evenamide across all clinical studies with evenamide to date, compared with one death among patients receiving placebo. Of the four deaths among patients receiving evenamide, three were considered unrelated to evenamide by the study investigators, while one was considered “possibly related” because two autopsies could not identify a definitive cause of death. The four deaths have been characterized by the FDA as a potential safety signal based on the possibility of a fatal arrhythmic mechanism, which cannot be definitively excluded through post hoc adjudication. Evenamide is also known to result in a very small shortening of the QTc interval on an electrocardiogram (ECG). Unlike QTc prolongation, there is no established risk or intervention threshold for QTc shortening, and a standard screening ECG does not reliably exclude latent sodium-channel disorders in asymptomatic patients.

Newron is reviewing the FDA’s feedback and the full body of safety data generated across the evenamide development program, which includes more than 10,000 ECGs from approximately 700 evenamide-treated subjects and input from independent cardiac electrophysiologists. Newron has not observed a pattern of cardiac abnormalities or arrhythmias in the preclinical and clinical safety data generated with evenamide to date. This includes a thorough QT study and more than 5,000 ECGs from over 700 patients with schizophrenia. As part of its response, Newron is also evaluating additional cardiac screening and monitoring measures for ENIGMA-TRS 2.

“We remain confident in the ENIGMA-TRS studies and encouraged by the program’s progress. Our belief in the potential of evenamide and its novel mechanism for patients with treatment-resistant schizophrenia remains strong,” said Ravi Anand, MD, Chief Medical Officer of Newron. “Patient safety is our utmost priority. Our team is working with high commitment to complete a thorough review of the FDA’s feedback and the available data, and to submit our response upon its completion. Our assessment is supported by the substantial body of preclinical and clinical safety data generated with evenamide. To date, we have not observed a pattern of cardiac abnormalities or arrhythmias. The four deaths among patients treated with evenamide represent an incidence of 0.56%, compared with one death and an incidence of 0.27% among patients receiving placebo. When adjusted for duration of treatment, the mortality rate was 1.31 per 100 patient-years for evenamide compared with 1.81 per 100 patient-years for placebo.”

Professor Dr. Peter Falkai, Chair Department of Psychiatry and Psychotherapy, LMU University of Munich, stated: “Schizophrenia is a tragic disease that affects patients in the teenage (males) and early twenties (females) and has a devastating effect on their lives. In addition to multiple episodes of psychosis and hospitalization, patients need to take antipsychotic medication with debilitating side-effects that makes them suffer from cardiac, hormonal, metabolic and motor disorders. Furthermore, schizophrenia reduces life-expectancy by about 10 years. TRS, a more severe form of the disease in which patients do not respond to any medication, reduces longevity by about 20 years.”
 

Investor Update Conference Call
Management will provide a brief update on the FDA clinical hold and ENIGMA-TRS development program. The call will be recorded and take place today at 3.30 pm CEST.

The access details:

Switzerland / Europe +41 (0) 58 310 50 00
United Kingdom +44 (0) 203 059 58 63
United States +1 (1) 631 570 56 13

Other international numbers available here.
 

About ENIGMA-TRS
ENIGMA-TRS 1
is an ongoing, international, 52-week, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics, including clozapine, will meet Treatment Response and Resistance Psychosis international consensus criteria for TRS. The study is expected to have enrolled at least 600 patients in the study by mid-October 2026, at study centers in 20 countries in Europe, Asia, Latin America, and Canada.

The primary assessment of efficacy and safety of ENIGMA-TRS 1 will be performed 12 weeks after randomization to treatment. Following this initial period, the study will continue to be double-blind and placebo-controlled until the 26- and 52-week time points. The primary efficacy endpoint of the trial will be the change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Newron expects to announce results from the 12-week primary endpoint assessment in Q1 2027.

ENIGMA-TRS 2 is taking place at centers in the U.S. and selected additional countries with the same screening procedure as the ENIGMA-TRS 1 trial. ENIGMA-TRS 2 will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase 3 study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide compared to placebo. In December 2025, ENIGMA-TRS 2 was initiated in the U.S., following approvals from the U.S, Food and Drug Administration (FDA) and the Institutional Review Board (IRB). The efficacy and safety analysis will be performed at the 12-week point following successful completion of the study. On April 29, 2026, Newron reported a hold by the FDA on the enrollment of new patients in the U.S. sites of the study. While U.S. patients entered screening, no U.S. patients have been dosed with evenamide, in the study.

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase 3 development program. Clinical trial results to date demonstrate the benefits of this drug candidate in TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com and connect with us on LinkedIn.

For more information, please contact:

Newron
Stefan Weber – CEO; +39 02 6103 46 26, pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com  

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
John Fraunces, LifeSci Advisors; +1 917 355 2395, jfraunces@lifesciadvisors.com
 

Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.


08.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Newron Pharmaceuticals S.p.A.
via Antonio Meucci 3
20091 Bresso
Italy
Phone: +39 02 610 3461
Fax: +39 02 610 34654
E-mail: pr@newron.com
Internet: www.newron.com
ISIN: IT0004147952
WKN: A0LF18
Listed: Regulated Unofficial Market in Dusseldorf (Primärmarkt); SIX
LEI Code: 8156002F8C11F80A9740
EQS News ID: 2412180

 
End of News EQS News Service

2412180  08.10.2026 CET/CEST